Alimera Sciences is a technology company.
Alimera Sciences has raised $94.0M across 4 funding rounds.
Alimera Sciences has raised $94.0M in total across 4 funding rounds.
Alimera Sciences has raised $94.0M in total across 4 funding rounds.
Alimera Sciences's investors include Domain Associates, HealthQuest Capital, Polaris Partners.
Alimera Sciences is a biopharmaceutical company specializing in the research, development, and commercialization of prescription ophthalmic pharmaceuticals for retinal diseases, such as diabetic macular edema, that can lead to vision loss.[1][2][3] Publicly traded on NASDAQ (ALIM) and headquartered in Alpharetta, Georgia, it serves ophthalmologists and patients by offering sustained-release treatments like Iluvien, an intravitreal insert approved in the US since 2015 and in about 20 European countries.[1][4][5] The company addresses unmet needs in retinal health amid aging populations, with products focused on the back of the eye where current therapies fall short, generating reported revenue around $90 million and employing about 154 people.[3]
Alimera Sciences was founded in June 2003 by C. Daniel Myers, David R. Holland, Daniel White, and Mark Testerman, all former colleagues from a large pharmaceutical company in ophthalmology who sought independence from big corporate directions.[1] The name "Alimera," derived loosely from ancient Greek meaning "day of truth," reflects their commitment to accountability in this new venture.[1] Early traction came in 2004 with Soothe Emollient Eye Drops for dry eyes, featuring Restoryl for lipid restoration in tears; this product was later sold to Bausch + Lomb.[1] The company has evolved to prioritize retinal disease treatments, with Iluvien becoming a key milestone after US commercialization in 2015.[1][4]
Alimera rides the wave of aging population-driven demand for retinal therapies, as diseases like diabetic retinopathy and macular degeneration affect millions and strain existing short-acting treatments.[1][3] Timing aligns with advances in sustained drug delivery, reducing injection frequency and improving patient compliance amid rising diabetes prevalence.[4] Market forces favoring smaller biopharma players include regulatory approvals for niche ophthalmics and partnerships for commercialization, positioning Alimera to influence retinal care ecosystems by filling gaps left by larger firms.[1][2][5]
Alimera is poised to expand its portfolio through licensing and acquisitions in ophthalmic drug delivery, potentially targeting new retinal indications like macular degeneration.[1][4][5] Trends in personalized, long-acting therapies and global aging will shape growth, with influence evolving via deeper physician integration and European/US market penetration. As a nimble player preserving vision, Alimera embodies the "day of truth" ethos, delivering targeted retinal solutions where need meets innovation.[1][5]
Alimera Sciences has raised $94.0M across 4 funding rounds. Most recently, it raised $5.0M Series C in September 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2009 | $5.0M Series C | Domain Associates, HealthQuest Capital, Polaris Partners | |
| Feb 1, 2008 | $30.0M Series C | Domain Associates, HealthQuest Capital, Polaris Partners | |
| Nov 1, 2005 | $32.0M Series B | Domain Associates, HealthQuest Capital, Polaris Partners | |
| Jul 1, 2004 | $27.0M Series A | Domain Associates, HealthQuest Capital, Polaris Partners |